Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0S7HM
|
||||
| Former ID |
DCL001071
|
||||
| Drug Name |
ENMD-2076
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Acute myeloid leukemia [ICD9: 205; ICD10:C92.0] | Phase 2 | [1], [2] | ||
| Company |
Entremed
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H25N7
|
||||
| InChI |
InChI=1S/C21H25N7/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26)/b9-8+
|
||||
| InChIKey |
BLQYVHBZHAISJM-CMDGGOBGSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Aurora kinase A | Target Info | Inhibitor | [3] | |
| KEGG Pathway | Oocyte meiosis | ||||
| Pathway Interaction Database | Aurora B signaling | ||||
| Signaling by Aurora kinases | |||||
| Integrin-linked kinase signaling | |||||
| PLK1 signaling events | |||||
| Aurora A signaling | |||||
| Reactome | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | ||||
| Regulation of PLK1 Activity at G2/M Transition | |||||
| WikiPathways | EGF/EGFR Signaling Pathway | ||||
| JAK/STAT | |||||
| Gastric Cancer Network 1 | |||||
| Integrated Breast Cancer Pathway | |||||
| APC/C-mediated degradation of cell cycle proteins | |||||
| References | |||||
| REF 1 | ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther. 2011 Jan;10(1):126-37. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7885). | ||||
| REF 3 | Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.